Market capitalization | $843.00m |
Enterprise Value | $395.73m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.33 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-208.57m |
Free Cash Flow (TTM) Free Cash Flow | $-157.82m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
10 Analysts have issued a Aeglea BioTherapeutics Inc forecast:
10 Analysts have issued a Aeglea BioTherapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -209 -209 |
63%
63%
|
EBIT (Operating Income) EBIT | -209 -209 |
62%
62%
|
Net Profit | -151 -151 |
59%
59%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
Head office | United States |
CEO | Cameron Turtle |
Employees | 65 |
Founded | 2013 |
Website | www.spyre.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.